Pure Global
NCT02153151

Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy

A Pilot Study to Evaluate the In-vitro Effect of AMP-514, a PD-1 Inhibitor, on Peripheral Blood T Cell Proliferation and Cytokine Production From Patients With Solid Malignancies Treated With Radiotherapy (RT)
Sidney Kimmel Cancer Center at Thomas Jefferson University·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
Cytology specimen
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Funder
Thomas Jefferson University
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 11, 2013
End date
Jul 14, 2016
Enrollment
21 participants
Primary outcome

Change in peripheral blood T cell proliferation (stimulation) and cytokine production in vitro

Summary

This pilot research trial studies the response in blood cells to AMP-514, a drug shown to
 increase immune response (capacity to fight against infections and cancer) against cancer in
 patients with solid tumors undergoing radiotherapy. Measuring changes in biomarkers may help
 doctors decide if AMP-514 should be combined with radiotherapy and when is the best time to
 combine the drug with radiation.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02153151
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02153151 through Pure Global AI's free database. This phase not specified trial is sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 21 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.